Replimune to Present at the Jefferies Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM ET. The event will be held at Marriott Marquis in New York. Founded in 2015, Replimune focuses on innovating tumor-directed oncolytic immunotherapies using its proprietary RPx platform. This platform utilizes an HSV-1 backbone to enhance immune responses against tumors while maintaining a strong safety profile. For more details, visit www.replimune.com.
Details
News Market Reaction – REPL
The recorded move for REPL in the trading session of this news was +4.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform offers a unique dual, local and systemic, mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.